An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cybin Inc. (NYSE American: CYBN) has announced that CEO Doug Drysdale will participate in a fireside chat during the H.C. Wainwright Global Investment Hybrid Conference from May 23-26, 2022, at Fontainebleau Miami Beach. The live webcast of the chat is scheduled for May 25, 2022, at 12:30 p.m. ET. Interested listeners can access the event through the company's investor relations website.
Cybin focuses on developing psychedelics into therapeutics, working with a network of partners to create effective treatments for mental health challenges.
Positive
None.
Negative
None.
TORONTO--(BUSINESS WIRE)--
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Hybrid Conference being held at the Fontainebleau Miami Beach May 23-26, 2022.
Mr. Drysdale’s fireside chat will be webcast live on Wednesday, May 25, 2022 at 12:30 p.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.
About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
